{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:10:54Z","timestamp":1783210254592,"version":"3.54.6"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute on Drug Abuse (NIDA) National Drug Abuse Treatment Clinical Trials Network","award":["UG1DA013714"],"award-info":[{"award-number":["UG1DA013714"]}]},{"name":"National Institute on Drug Abuse (NIDA) National Drug Abuse Treatment Clinical Trials Network","award":["UG1DA049436"],"award-info":[{"award-number":["UG1DA049436"]}]},{"name":"National Institute on Drug Abuse (NIDA) National Drug Abuse Treatment Clinical Trials Network","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}]},{"name":"NIDA and NIAAA","award":["R25-DA050687-01A1"],"award-info":[{"award-number":["R25-DA050687-01A1"]}]},{"name":"Gilead FOCUS partnership","award":["2344"],"award-info":[{"award-number":["2344"]}]},{"name":"NIDA","award":["R01DA054703"],"award-info":[{"award-number":["R01DA054703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-024-00721-0","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:51:31Z","timestamp":1736902291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["HIV Prevention in Syringe Service Programs Since the Start of COVID-19: Where Do We Go From Here?"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-9493","authenticated-orcid":false,"given":"Mary A.","family":"Hatch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1022-1777","authenticated-orcid":false,"given":"Melissa","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Closs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-5508","authenticated-orcid":false,"given":"Susana","family":"Keeshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-7214","authenticated-orcid":false,"given":"Judith","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"721_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). Determination of need for syringe services programs. 2023. Available: https:\/\/www.cdc.gov\/syringe-services-programs\/php\/need-determination\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ssp\/determination-of-need-for-ssp.html. Accessed 09 Aug 2024."},{"issue":"1","key":"721_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ije\/dyt243","volume":"43","author":"EJ Aspinall","year":"2014","unstructured":"Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235\u201348.","journal-title":"Int J Epidemiol"},{"key":"721_CR3","unstructured":"Centers for Disease Control and Prevention (CDC). Safety and effectiveness of syringe services programs. 2024. Available: https:\/\/www.cdc.gov\/syringe-services-programs\/php\/safety-effectiveness.html. Accessed 01 Aug 2024."},{"key":"721_CR4","unstructured":"Centers for Disease Control and Prevention (CDC). Compendium of evidence-based interventions and best practices for HIV prevention. 2024. Available: https:\/\/www.cdc.gov\/hiv\/research\/interventionresearch\/compendium\/index.html. Accessed 01 Aug 2024."},{"key":"721_CR5","unstructured":"Centers for Disease Control and Prevention (CDC). U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 Update. A clinical practice guideline. 2021. Available: https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021.pdf. Accessed 01 Aug 2024."},{"key":"721_CR6","unstructured":"Centers for Disease Control and Prevention (CDC). Ending the HIV epidemic in the U.S.: accomplishments. 2023. Available: https:\/\/files.hiv.gov\/s3fs-public\/2023-07\/CDC-EHE-Accomplishments.pdf. Accessed 01 Aug 2024."},{"issue":"9","key":"721_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844\u20135. https:\/\/doi.org\/10.1001\/jama.2019.1343.","journal-title":"JAMA"},{"key":"721_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15585\/mmwr.mm7102a4","volume":"71","author":"RB Hershow","year":"2022","unstructured":"Hershow RB, Wilson S, Bonacci RA, Deutsch-Feldman M, Russell OO, Young S, et al. Notes from the field: HIV outbreak during the COVID-19 pandemic among persons who inject drugs \u2014 Kanawha County, West Virginia, 2019\u20132021. MMWR Morb Mortal Wkly Rep. 2022;71:66\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7102a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"721_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, Jones CM, Flanagan BE, Siddiqi AE, Iqbal K, Dent AL, Mermin JH, McCray E, Ward JW, Brooks JT. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323\u201331. https:\/\/doi.org\/10.1097\/QAI.0000000000001098.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"721_CR10","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s10461-020-02988-x","volume":"25","author":"CB Mistler","year":"2021","unstructured":"Mistler CB, Copenhaver MM, Shrestha R. The pre-exposure Prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. AIDS Behav. 2021;25(5):1490\u2013506. https:\/\/doi.org\/10.1007\/s10461-020-02988-x. PMID: 32749627; PMCID: PMC7858689.","journal-title":"AIDS Behav"},{"key":"721_CR11","unstructured":"Centers for Disease Control and Prevention (CDC). Clinical guidance for PrEP. 2024. Available: https:\/\/www.gov\/hivnexus\/hcp\/prep\/index.html. Accessed 05 Sep 2024."},{"issue":"1","key":"721_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13722-024-00476-4","volume":"19","author":"MT Harris","year":"2024","unstructured":"Harris MT, Weinberger E, O\u2019Brien C, Althoff M, Paltrow-Krulwich S, Taylor JL, et al. PrEP facilitators and barriers in substance use bridge clinics for women who engage in sex work and who use drugs. Addict Sci Clin Pract. 2024;19(1):47. https:\/\/doi.org\/10.1186\/s13722-024-00476-4. PMID: 38831359; PMCID: PMC11145858.","journal-title":"Addict Sci Clin Pract"},{"key":"721_CR13","doi-asserted-by":"publisher","unstructured":"Forman E, Roth AM, Huffaker S, Lurano R, Eger WH, Akiba C et al. The landscape of HIV services delivery in U.S. syringe services programs: a qualitative exploration of current models and opportunities. Oral presentation at the 2024 college on problems of drug dependence. 2024. https:\/\/doi.org\/10.1186\/s12954-023-00839-1","DOI":"10.1186\/s12954-023-00839-1"},{"key":"721_CR14","doi-asserted-by":"publisher","unstructured":"Carter G, Meyerson B, Rivers P, Crosby R, Lawrence C, Cope SD et al. Living at the confluence of stigmas: PrEP awareness and feasibility among people who inject drugs in two predominantly rural states. AIDS Behav. 2021;25(10):3085\u20133096. https:\/\/doi.org\/10.1007\/s10461-021-03304-x. Epub 2021 May 18. PMID: 34003385.","DOI":"10.1007\/s10461-021-03304-x"},{"issue":"9","key":"721_CR15","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1007\/s10461-020-02886-2","volume":"24","author":"SN Glick","year":"2020","unstructured":"Glick SN, Prohaska SM, LaKosky PA, Juarez AM, Corcorran MA, Des Jarlais DC. The impact of COVID-19 on syringe services programs in the United States. AIDS Behav. 2020;24(9):2466\u20138. https:\/\/doi.org\/10.1007\/s10461-020-02886-2.","journal-title":"AIDS Behav"},{"issue":"1","key":"721_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12954-022-00661-1","volume":"19","author":"A Wang","year":"2022","unstructured":"Wang A, Jawa R, Mackin S, Whynott L, Buchholz C, Childs E, et al. We were building the plane as we were flying it, and we somehow made it to the other end: syringe service program staff experiences and well-being during the COVID-19 pandemic. Harm Reduct J. 2022;19(1):78. https:\/\/doi.org\/10.1186\/s12954-022-00661-1.","journal-title":"Harm Reduct J"},{"issue":"5","key":"721_CR17","doi-asserted-by":"publisher","first-page":"e39023","DOI":"10.7759\/cureus.39023","volume":"15","author":"D Pietrantoni","year":"2023","unstructured":"Pietrantoni D, Barroca C, Lynch S, Byrne J, Ortner M, Kotwani R, et al. A scoping review on the effects of COVID-19 on syringe service programs in the United States. Cureus. 2023;15(5):e39023. https:\/\/doi.org\/10.7759\/cureus.39023.","journal-title":"Cureus"},{"issue":"8","key":"721_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/14787210.2023.2239503","volume":"21","author":"JYH Kim","year":"2023","unstructured":"Kim JYH, Barth SK, Monroe AK, Ahsan S, Kovacic J, Senn S, et al. The impact of COVID-19 on the HIV continuum of care: challenges, innovations, and opportunities. Expert Rev Anti Infect Ther. 2023;21(8):831\u201346. https:\/\/doi.org\/10.1080\/14787210.2023.2239503.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"13","key":"721_CR19","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/QAD.0000000000003305","volume":"36","author":"CE Spears","year":"2022","unstructured":"Spears CE, Taylor BS, Liu AY, Levy SM, Eaton EF. Intersecting epidemics: the impact of coronavirus disease 2019 on the HIV prevention and care continua in the United States. AIDS. 2022;36(13):1749\u201359. https:\/\/doi.org\/10.1097\/QAD.0000000000003305.","journal-title":"AIDS"},{"issue":"1","key":"721_CR20","first-page":"10","volume":"7","author":"C Ozgur","year":"2024","unstructured":"Ozgur C, Fedor K, Kois A, McFarland E. The effect of supply chain disruptions on business post COVID-19. Eng Technol Q Reviews. 2024;7(1):10\u201323. https:\/\/ssrn.com\/abstract=4792429.","journal-title":"Eng Technol Q Reviews"},{"issue":"7","key":"721_CR21","doi-asserted-by":"publisher","first-page":"e0318920","DOI":"10.1128\/jcm.03189-20","volume":"61","author":"NE Cornish","year":"2023","unstructured":"Cornish NE, Bachmann LH, Diekema DJ, McDonald LC, McNult P, Stevens-Garcia J, et al. Pandemic demand for SARS-CoV-2 testing led to critical supply and workforce shortages in U.S. clinical and public health laboratories. J Clin Microbiol. 2023;61(7):e0318920. https:\/\/doi.org\/10.1128\/jcm.03189-20.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"721_CR22","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s10461-022-03941-w","volume":"27","author":"C Hong","year":"2023","unstructured":"Hong C. Characterizing the impact of the COVID-19 pandemic on HIV PrEP care: a review and synthesis of the literature. AIDS Behav. 2023;27(7):2089\u2013102. https:\/\/doi.org\/10.1007\/s10461-022-03941-w.","journal-title":"AIDS Behav"},{"issue":"1","key":"721_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12954-023-00861-3","volume":"20","author":"TS Bartholomew","year":"2023","unstructured":"Bartholomew TS, Tookes HE, Chueng TA, Bluthenthal RN, Wenger LD, Kral AH, et al. Availability of telehealth-based services at syringe services programs under the COVID-19 public health emergency. Harm Reduct J. 2023;20(1):122. https:\/\/doi.org\/10.1186\/s12954-023-00861-3.","journal-title":"Harm Reduct J"},{"issue":"1","key":"721_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12954-024-00961-8","volume":"21","author":"C Scaramutti","year":"2024","unstructured":"Scaramutti C, Hervera B, Rivera Y, Chueng TA, Forrest DW, Suarez E Jr, et al. Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma. Harm Reduct J. 2024;21(1):50. https:\/\/doi.org\/10.1186\/s12954-024-00961-8.","journal-title":"Harm Reduct J"},{"issue":"6","key":"721_CR25","doi-asserted-by":"publisher","first-page":"e37479","DOI":"10.2196\/37479","volume":"8","author":"P Patel","year":"2022","unstructured":"Patel P, Kerzner M, Reed JB, Sullivan PS, El-Sadr WM. Public health implications of adapting HIV pre-exposure prophylaxis programs for virtual service delivery in the context of the COVID-19 pandemic: systematic review. JMIR Public Health Surveill. 2022;8(6):e37479. https:\/\/doi.org\/10.2196\/37479.","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"721_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13721-021-00300-y","volume":"10","author":"CA Clare","year":"2021","unstructured":"Clare CA. Telehealth and the digital divide as a social determinant of health during the COVID-19 pandemic. Netw Model Anal Health Inf Bioinform. 2021;10(1):26. https:\/\/doi.org\/10.1007\/s13721-021-00300-y.","journal-title":"Netw Model Anal Health Inf Bioinform"},{"issue":"5 Suppl 1","key":"721_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.amepre.2021.05.044","volume":"61","author":"D Broz","year":"2021","unstructured":"Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs\u2019 role in ending the HIV epidemic in the U.S.: why we cannot do it without them. Am J Prev Med. 2021;61(5 Suppl 1):118\u201329. https:\/\/doi.org\/10.1016\/j.amepre.2021.05.044.","journal-title":"Am J Prev Med"},{"issue":"S1","key":"721_CR28","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1097\/QAI.000000000000298","volume":"90","author":"DH Li","year":"2022","unstructured":"Li DH, Benbow N, Keiser B, Mongrella M, Ortiz K, Villamar J, et al. Determinants of implementation for HIV pre-exposure prophylaxis based on an updated consolidated framework for implementation research: a systematic review. J Acquir Immune Defic Syndr. 2022;90(S1):S235\u201346. https:\/\/doi.org\/10.1097\/QAI.000000000000298.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"721_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13722-024-00478-2","volume":"19","author":"JL Merle","year":"2024","unstructured":"Merle JL, Zapata JP, Quieroz A, Zamantakis A, Sanuade O, Mustanski B, et al. Pre-exposure prophylaxis (PrEP) among people who use drugs: a qualitative scoping review of implementation determinants and change methods. Addict Sci Clin Pract. 2024;19(1):46. https:\/\/doi.org\/10.1186\/s13722-024-00478-2.","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"721_CR30","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s10461-024-04331-0","volume":"28","author":"JL Merle","year":"2024","unstructured":"Merle JL, Benbow N, Li DH, Zapata JP, Queiroz A, Zamantakis A, et al. Improving delivery and use of HIV pre-exposure prophylaxis in the US: a systematic review of implementation strategies and adjunctive interventions. AIDS Behav. 2024;28(7):2321\u201339. https:\/\/doi.org\/10.1007\/s10461-024-04331-0.","journal-title":"AIDS Behav"},{"issue":"5","key":"721_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1521\/aeap.2018.30.5.369","volume":"30","author":"M Felsher","year":"2018","unstructured":"Felsher M, Szep Z, Krakower D, Martinez-Donate A, Tran N, Roth AM. I don\u2019t need prep right now: a qualitative exploration of the barriers to prep care engagement through the application of the health belief model. AIDS Edu Prev. 2018;30(5):369\u201381. https:\/\/doi.org\/10.1521\/aeap.2018.30.5.369.","journal-title":"AIDS Edu Prev"},{"issue":"12","key":"721_CR32","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1007\/s10461-021-03353-2","volume":"25","author":"SM Walters","year":"2021","unstructured":"Walters SM, Platt J, Anakaraonye A, Golub SA, Cunningham CO, Norton BL, et al. Considerations for the design of pre-exposure prophylaxis (prep) interventions for women: lessons learned from the implementation of a novel prep intervention. AIDS Behav. 2021;25(12):3987\u201399. https:\/\/doi.org\/10.1007\/s10461-021-03353-2.","journal-title":"AIDS Behav"},{"key":"721_CR33","unstructured":"Oregon Health Authority. HIV data. Oregon Public Health Division. Chime in survey. 2022. Available: https:\/\/www.oregon.gov\/oha\/PH\/DISEASESCONDITIONS\/COMMUNICABLEDISEASE\/DISEASESURVEILLANCEDATA\/HIVDATA\/Pages\/chimein.aspx. Accessed 01 Aug 2024."},{"key":"721_CR34","doi-asserted-by":"publisher","first-page":"113809","DOI":"10.1016\/j.socscimed.2021.113809","volume":"275","author":"M Felsher","year":"2021","unstructured":"Felsher M, Ziegler E, Amico KR, Carrico A, Coleman J, Roth AM. PrEP just isn\u2019t my priority: adherence challenges among women who inject drugs participating in a pre-exposure prophylaxis (PrEP) demonstration project in Philadelphia, PA USA. Soc Sci Med. 2021;275:113809. Epub 2021 Mar 4. PMID: 33735778; PMCID: PMC8009846. https:\/\/doi.org\/10.1016\/j.socscimed.2021.113809.","journal-title":"Soc Sci Med"},{"key":"721_CR35","unstructured":"Kingston S, Newman A, Banta-Green C, Glick S. Results from the 2023 WA state syringe services program health survey. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington. 2024. Available https:\/\/adai.uw.edu\/download\/9208\/. Accessed 01 Aug 2024."},{"issue":"5","key":"721_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11904-022-00619-9","volume":"19","author":"KE Lancaster","year":"2022","unstructured":"Lancaster KE, Endres-Dighe S, Sucaldito AD, Piscalko H, Madhu A, Kiriazova T, et al. Measuring and addressing stigma within HIV interventions for people who use drugs: a scoping review of recent research. Curr HIV\/AIDS Rep. 2022;19(5):301\u201311. https:\/\/doi.org\/10.1007\/s11904-022-00619-9.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"721_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/apc.2015.0163","volume":"30","author":"AF Camacho-Gonzalez","year":"2016","unstructured":"Camacho-Gonzalez AF, Wallins A, Toledo L, Murray A, Gaul Z, Sutton MY, et al. Risk factors for HIV Transmission and barriers to HIV Disclosure: Metropolitan Atlanta Youth perspectives. AIDS Patient Care STDS. 2016;30(1):18\u201324. https:\/\/doi.org\/10.1089\/apc.2015.0163. Epub 2015 Nov 20. PMID: 26588663; PMCID: PMC4717512.","journal-title":"AIDS Patient Care STDS"},{"key":"721_CR38","doi-asserted-by":"publisher","unstructured":"Bradford D, Parman M, Levy S, Turner WH, Li L, Leisch L, et al. HIV and Addiction Services for people who inject drugs: Healthcare Provider perceptions on Integrated Care in the U.S. South. J Prim Care Community Health. 2023 Jan-Dec;14:21501319231161208.\u2009https:\/\/doi.org\/10.1177\/21501319231161208.","DOI":"10.1177\/21501319231161208"},{"issue":"1","key":"721_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12954-024-00991-2","volume":"21","author":"NE Cunningham","year":"2024","unstructured":"Cunningham NE, Lamb J, Staller A, Krajden M, Hogg RS, Towle A, et al. Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada. Harm Reduct J. 2024;21(1):75. https:\/\/doi.org\/10.1186\/s12954-024-00991-2.","journal-title":"Harm Reduct J"},{"issue":"6","key":"721_CR40","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11904-023-00685-7","volume":"20","author":"JJ Lee","year":"2023","unstructured":"Lee JJ, Li Verdugo J, Xiao AY, Vo K. Digital interventions to enhance PrEP uptake and adherence through stigma reduction. Curr HIV\/AIDS Rep. 2023;20(6):458\u201369. https:\/\/doi.org\/10.1007\/s11904-023-00685-7.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"721_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2046147X211067002","volume":"11","author":"R Dimitrov","year":"2022","unstructured":"Dimitrov R, Jelen A, L\u2019Etang J. Taboos in health communication: Stigma, silence and voice. Public Rel Inq. 2022;11(1):3\u20135. https:\/\/doi.org\/10.1177\/2046147X211067002.","journal-title":"Public Rel Inq"},{"issue":"4","key":"721_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/15332640.2017.1292418","volume":"16","author":"C McKnight","year":"2017","unstructured":"McKnight C, Shumway M, Masson CL, Pouget ER, Jordan AE, Des Jarlais DC, et al. Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. J Ethn Subst Abuse. 2017;16(4):404\u201319.","journal-title":"J Ethn Subst Abuse"},{"key":"721_CR43","doi-asserted-by":"publisher","first-page":"112384","DOI":"10.1016\/j.socscimed.2019.112384","volume":"234","author":"AB Collins","year":"2019","unstructured":"Collins AB, Boyd J, Cooper HL, McNeil R. The intersectional risk environment of people who use drugs. Soc Sci Med. 2019;234:112384. https:\/\/doi.org\/10.1016\/j.socscimed.2019.112384.","journal-title":"Soc Sci Med"},{"issue":"2","key":"721_CR44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11673-023-10260-9","volume":"20","author":"CAR Malatzky","year":"2023","unstructured":"Malatzky CAR, Couch DL. The power in Rural Place Stigma. J Bioeth Inq. 2023;20(2):237\u201348. https:\/\/doi.org\/10.1007\/s11673-023-10260-9.","journal-title":"J Bioeth Inq"},{"issue":"4","key":"721_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/10826084.2019.1673419","volume":"55","author":"A Edeza","year":"2020","unstructured":"Edeza A, Bazzi A, Salhaney P, Biancarelli D, Childs E, Mimiaga MJ. HIV pre-exposure prophylaxis for people who inject drugs: the context of co-occurring injection-and sexual-related HIV risk in the US Northeast. Subst Use Misuse. 2020;55(4):525\u201333. https:\/\/doi.org\/10.1080\/10826084.2019.1673419.","journal-title":"Subst Use Misuse"},{"issue":"7","key":"721_CR46","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1007\/s10461-022-03971-4","volume":"27","author":"JG Rosen","year":"2023","unstructured":"Rosen JG, Zhang L, Pelaez D, Park JN, Glick JL. A capacity-strengthening intervention to support HIV pre-exposure prophylaxis (PrEP) awareness-building and promotion by frontline harm reduction workers in Baltimore, Maryland: a mixed methods evaluation. AIDS Behav. 2023;27(7):2440\u201353. https:\/\/doi.org\/10.1007\/s10461-022-03971-4.","journal-title":"AIDS Behav"},{"key":"721_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.trsl.2021.03.011","volume":"234","author":"LD Wenger","year":"2021","unstructured":"Wenger LD, Kral AH, Bluthenthal RN, Morris T, Ongais L, Lambdin BH. Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises. Transl Res. 2021;234:159\u201373. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.011.","journal-title":"Transl Res"},{"key":"721_CR48","doi-asserted-by":"publisher","first-page":"103825","DOI":"10.1016\/j.drugpo.2022.103825","volume":"109","author":"EJ Austin","year":"2022","unstructured":"Austin EJ, Corcorran MA, Briggs ES, Frost MC, Behrends CN, Juarez AM, et al. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: a mixed methods study of syringe services program perspectives. Int J Drug Policy. 2022;109:103825. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103825.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"721_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10461-021-03332-7","volume":"26","author":"MC Frost","year":"2022","unstructured":"Frost MC, Sweek EW, Austin EJ, Corcorran MA, Juarez AM, Frank ND, et al. Program adaptations to provide harm reduction services during the COVID-19 pandemic: a qualitative study of syringe services programs in the U.S. AIDS Behav. 2022;26(1):57\u201368. https:\/\/doi.org\/10.1007\/s10461-021-03332-7.","journal-title":"AIDS Behav"},{"issue":"1","key":"721_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/0033354921994202","volume":"137","author":"NW Furukawa","year":"2022","unstructured":"Furukawa NW, Weimer M, Willenburg KS, Kilkenny ME, Atkins AD, Paul McClung R, et al. Expansion of preexposure prophylaxis capacity in response to an HIV outbreak among people who inject Drugs-Cabell County, West Virginia, 2019. Public Health Rep. 2022;137(1):25\u201331. https:\/\/doi.org\/10.1177\/0033354921994202.","journal-title":"Public Health Rep"},{"issue":"5","key":"721_CR51","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s10461-020-02979-y","volume":"25","author":"OJ Blackstock","year":"2021","unstructured":"Blackstock OJ, Platt J, Golub SA, Anakaraonye AR, Norton BL, Walters SM, et al. A pilot study to evaluate a novel pre-exposure prophylaxis peer outreach and navigation intervention for women at high risk for HIV infection. AIDS Behav. 2021;25(5):1411\u201322. https:\/\/doi.org\/10.1007\/s10461-020-02979-y.","journal-title":"AIDS Behav"},{"issue":"1","key":"721_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12954-018-0263-5","volume":"15","author":"KB Biello","year":"2018","unstructured":"Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55. https:\/\/doi.org\/10.1186\/s12954-018-0263-5.","journal-title":"Harm Reduct J"},{"issue":"3","key":"721_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/apc.2019.0189","volume":"34","author":"B Pleuhs","year":"2020","unstructured":"Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Health care provider barriers to HIV pre-exposure prophylaxis in the United States: a systematic review. AIDS Patient Care STDS. 2020;34(3):111\u201323. https:\/\/doi.org\/10.1089\/apc.2019.0189. Epub 2020 Feb 28.","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"721_CR54","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s10461-016-1625-1","volume":"21","author":"AE Petroll","year":"2017","unstructured":"Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256\u201367. https:\/\/doi.org\/10.1007\/s10461-016-1625-1.","journal-title":"AIDS Behav"},{"issue":"7","key":"721_CR55","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/apc.2022.0068","volume":"36","author":"AR Bazzi","year":"2022","unstructured":"Bazzi AR, Valasek CJ, Streuli SA, Vera CF, Harvey-Vera A, Philbin MM, et al. Long-acting injectable human immunodeficiency virus pre-exposure prophylaxis preferred over other modalities among people who inject drugs: findings from a qualitative study in California. AIDS Patient Care STDs. 2022;36(7):254\u201362. https:\/\/doi.org\/10.1089\/apc.2022.0068.","journal-title":"AIDS Patient Care STDs"},{"issue":"5","key":"721_CR56","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s10461-024-04285-3","volume":"28","author":"WH Eger","year":"2024","unstructured":"Eger WH, Bazzi AR, Valasek CJ, Vera CF, Harvey-Vera A, Artamonova I, et al. Long-acting injectable PrEP interest and general PrEP awareness among people who inject drugs in the San Diego-Tijuana border metroplex. AIDS Behav. 2024;28(5):1650\u201361. https:\/\/doi.org\/10.1007\/s10461-024-04285-3.","journal-title":"AIDS Behav"},{"issue":"1","key":"721_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10461-022-03816-0","volume":"27","author":"K Meyers","year":"2023","unstructured":"Meyers K, Nguyen N, Zucker JE, Kutner BA, Carnevale C, Castor D, et al. The long-acting cabotegravir tail as an implementation challenge: planning for safe discontinuation. AIDS Behav. 2023;27(1):4\u20139. https:\/\/doi.org\/10.1007\/s10461-022-03816-0.","journal-title":"AIDS Behav"},{"issue":"7","key":"721_CR58","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","volume":"7","author":"RJ Landovitz","year":"2020","unstructured":"Landovitz RJ, Li S, Eron JJ, Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472\u201381. https:\/\/doi.org\/10.1016\/S2352-3018(20)30106-5.","journal-title":"Lancet HIV"},{"issue":"7","key":"721_CR59","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"N Engl J Med"},{"key":"721_CR60","unstructured":"Landovitz RJ, Donnell D, Ha T, Kallas EG, Magnus M. CAB-LA PrEP keeps advantage over TDF\/FTC in 1-year unblinded phase- seven breakthrough infections despite on-time CAB-LA injections. Paper presented at: CROI 2022, February 12\u201316 and 22\u201324. 2022."},{"key":"721_CR61","doi-asserted-by":"publisher","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Gurrion Ouma S, Hunidzarira P, Kalonji D et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial [published correction appears in Lancet. 2022;399(10337):1778. https:\/\/doi.org\/10.1016\/S0140-6736(22)00783-8]. Lancet. 2022;399(10337):1779\u20131789. https:\/\/doi.org\/10.1016\/S0140-6736(22)00538-4","DOI":"10.1016\/S0140-6736(22)00783-8"},{"issue":"4","key":"721_CR62","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/COH.0000000000000733","volume":"17","author":"MA Spinelli","year":"2022","unstructured":"Spinelli MA, Grinsztejn B, Landovitz RJ. Promises and challenges: cabotegravir for preexposure prophylaxis. Curr Opin HIV AIDS. 2022;17(4):186\u201391. https:\/\/doi.org\/10.1097\/COH.0000000000000733. Epub 2022 Mar 4.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"721_CR63","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.japh.2021.11.024","volume":"62","author":"K Whelchel","year":"2022","unstructured":"Whelchel K, Zuckerman AD, DeClercq J, Choi L, Rashid S, Kelly SG. HIV PrEP access and affordability: a multidisciplinary specialty pharmacy model. J Am Pharm Assoc. 2022;62(3):853\u20138. https:\/\/doi.org\/10.1016\/j.japh.2021.11.024.","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"721_CR64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2105\/AJPH.2019.305389","volume":"110","author":"ES Kay","year":"2020","unstructured":"Kay ES, Pinto RM. Is insurance a barrier to HIV preexposure prophylaxis? Clarifying the issue. Am J Public Health. 2020;110(1):61\u20134. https:\/\/doi.org\/10.2105\/AJPH.2019.305389.","journal-title":"Am J Public Health"},{"issue":"12","key":"721_CR65","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1007\/s11606-023-08142-2","volume":"38","author":"SA Springer","year":"2023","unstructured":"Springer SA. Ending the HIV epidemic for persons who use drugs: the practical challenges of meeting people where they are. J Gen Intern Med. 2023;38(12):2816\u20138. https:\/\/doi.org\/10.1007\/s11606-023-08142-2.","journal-title":"J Gen Intern Med"},{"key":"721_CR66","unstructured":"Angst S, Rosen J, De Gregorio S, Painter G, Belonging Institute. Housing affordability in the wake of COVID-19. Othering and. 2021. Housing Policy Brief. https:\/\/belonging.berkeley.edu\/sites\/default\/files\/Angst%20et%20al%20Housing%20Affordability%20COVID%20SoCal%20Region.pdf"},{"issue":"4","key":"721_CR67","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11606-022-07672-5","volume":"38","author":"AR Bazzi","year":"2023","unstructured":"Bazzi AR, Shaw LC, Biello KB, Vahey S, Brody JK. Patient and provider perspectives on a novel, low-threshold HIV PrEP program for people who inject drugs experiencing homelessness. J Gen Intern Med. 2023;38(4):913\u201321. https:\/\/doi.org\/10.1007\/s11606-022-07672-5.","journal-title":"J Gen Intern Med"},{"key":"721_CR68","doi-asserted-by":"publisher","first-page":"1360349","DOI":"10.3389\/fpubh.2024.1360349","volume":"12","author":"A Chory","year":"2024","unstructured":"Chory A, Bond K. Access to PrEP and other sexual health services for cisgender women in the United States: a review of state policy and Medicaid expansion. Front Public Health. 2024;12:1360349. https:\/\/doi.org\/10.3389\/fpubh.2024.1360349.","journal-title":"Front Public Health"},{"issue":"3","key":"721_CR69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.amepre.2020.10.021","volume":"60","author":"BF Farkhad","year":"2021","unstructured":"Farkhad BF, Holtgrave DR, Albarrac\u00edn D. Effect of Medicaid expansions on HIV diagnoses and pre-exposure prophylaxis use. Am J Prev Med. 2021;60(3):335\u201342. https:\/\/doi.org\/10.1016\/j.amepre.2020.10.021.","journal-title":"Am J Prev Med"},{"key":"721_CR70","unstructured":"Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2018\u20132022. HIV Surveill Suppl Rep. 2024;29(1). https:\/\/www.cdc.gov\/hiv-data\/nhss\/estimated-hiv-incidence-and-prevalence.html. Accessed 13 Sep 2024."},{"key":"721_CR71","unstructured":"Centers for Medicare and Medicaid Services (CMS). Unwinding and returning to regular operations after COVID-19. 2019. Available: https:\/\/www.medicaid.gov\/resources-for-states\/coronavirus-disease-2019-covid-19\/unwinding-and-returning-regular-operations-after-covid-19\/index.html. Accessed 01 Aug 2024."},{"key":"721_CR72","unstructured":"Legislative Analysis and Public Policy Association. Syringe services programs: summary of state laws. 2023. Available: https:\/\/legislativeanalysis.org\/syringe-services-programs-summary-of-state-laws\/. Accessed 16 Jul 2024."},{"key":"721_CR73","unstructured":"WV News Report. West Virginia House Bill 4866 aims to end needle exchange programs, transition to other harm reduction services. 2024. Available: https:\/\/www.wvnews.com\/news\/wvnews\/west-virginia-house-bill-4866-aims-to-end-needle-exchange-programs-transition-to-other-harm\/article_5e5b67cc-b594-11ee-b818-5b496f9ae6f0.html. Accessed 05 Sep 2024."},{"key":"721_CR74","doi-asserted-by":"publisher","first-page":"iii7","DOI":"10.1093\/jurban\/jtg078","volume":"80","author":"SA Strathdee","year":"2003","unstructured":"Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80:iii7\u201314. https:\/\/doi.org\/10.1093\/jurban\/jtg078.","journal-title":"J Urban Health"},{"issue":"12","key":"721_CR75","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/cid\/ciz1236","volume":"71","author":"JL Marcus","year":"2020","unstructured":"Marcus JL, Paltiel AD, Walensky RP. Has pre-exposure prophylaxis made a difference at a population level? Jury is still out. Clin Infect Dis. 2020;71(12):3152\u20133. https:\/\/doi.org\/10.1093\/cid\/ciz1236. PMID: 32097454; PMCID: PMC7819505.","journal-title":"Clin Infect Dis"},{"key":"721_CR76","doi-asserted-by":"publisher","unstructured":"Bradley H, Luisi N, Carter A, Pigott T, Abramovitz D, Allen S et al. Assessing Covid-19 pandemic impacts on the health of PWID using a novel data sharing model. 2024. Available: https:\/\/ouci.dntb.gov.ua\/en\/works\/9ZRomVb9\/. Accessed 05 Jul 2024. https:\/\/doi.org\/10.2139\/ssrn.4878315","DOI":"10.2139\/ssrn.4878315"},{"key":"721_CR77","doi-asserted-by":"publisher","unstructured":"McBrien KA, Ivers N, Barnieh L, Bailey JJ, Lorenzetti DL, Nicholas D et al. Patient navigators for people with chronic disease: a systematic review. PLoS ONE. 2018;13(2):e0191980. https:\/\/doi.org\/10.1371\/journal.pone.a191980.","DOI":"10.1371\/journal.pone.a191980"},{"key":"721_CR78","doi-asserted-by":"publisher","unstructured":"Faro EZ, Mantell JE, Gonzalez-Argoti T, Hoffman S, Edelstein Z, Tsoi B, et al. Implementing prep services in diverse health care settings. J Acquir Immune Defic Syndr. 2022;90(S1). https:\/\/doi.org\/10.1097\/qai.0000000000002971.","DOI":"10.1097\/qai.0000000000002971"},{"issue":"4","key":"721_CR79","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s10461-022-03853-9","volume":"27","author":"S Tross","year":"2023","unstructured":"Tross S, Spector AY, Ertl MM, Berg H, Turrigiano E, Hoffman S. A qualitative study of barriers and facilitators of PrEP uptake among women in substance use treatment and syringe service programs. AIDS Behav. 2023;27(4):1162\u201372. https:\/\/doi.org\/10.1007\/s10461-022-03853-9. Epub 2022 Nov 1. PMID: 36318430; PMCID: PMC10796210.","journal-title":"AIDS Behav"},{"key":"721_CR80","doi-asserted-by":"publisher","first-page":"111133","DOI":"10.1016\/j.drugalcdep.2024.111133","volume":"257","author":"MA Hatch","year":"2024","unstructured":"Hatch MA, Laschober TC, Paschen-Wolff M, Ertl MM, Nelson CM, Wright L, et al. PrEP for people who use opioids: a NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high. Drug Alcohol Depend. 2024;257:111133. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111133. Epub 2024 Feb 23. PMID: 38447393; PMCID: PMC11131129.","journal-title":"Drug Alcohol Depend"},{"key":"721_CR81","doi-asserted-by":"publisher","unstructured":"Bartholomew TS, Andraka-Cristou B, Totaram RK, Harris S, Doblecki-Lewis S, Ostrer L, et al. We want everything in a one-stop shop: acceptability and feasibility of prep and buprenorphine implementation with mobile syringe services for black people who inject drugs. Harm Reduct J. 2022;19(1). https:\/\/doi.org\/10.1186\/s12954-022-00721-6.","DOI":"10.1186\/s12954-022-00721-6"},{"issue":"3","key":"721_CR82","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/qai.000000000000255","volume":"86","author":"AM Roth","year":"2021","unstructured":"Roth AM, Tran NK, Felsher M, Gadegbeku AB, Piecara B, Fox R, et al. Integrating HIV preexposure prophylaxis with community-based syringe services for women who inject drugs: results from the project SHE demonstration study. J Acquir Immune Defi Syndr. 2021;86(3):e61\u201370. https:\/\/doi.org\/10.1097\/qai.000000000000255.","journal-title":"J Acquir Immune Defi Syndr"},{"issue":"6","key":"721_CR83","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11904-021-00578-7","volume":"18","author":"E Rousseau","year":"2021","unstructured":"Rousseau E, Julies RF, Madubela N, Kassim S. Novel platforms for Biomedical HIV Prevention Delivery to Key populations - community Mobile clinics, Peer-Supported, pharmacy-led PrEP delivery, and the Use of Telemedicine. Curr HIV\/AIDS Rep. 2021;18(6):500\u20137. https:\/\/doi.org\/10.1007\/s11904-021-00578-7. Epub 2021 Oct 27. PMID: 34708316; PMCID: PMC8549812.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"721_CR84","doi-asserted-by":"publisher","unstructured":"Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Curr HIV\/AIDS Rep. 2019;16(1):113\u2013119. https:\/\/doi.org\/10.1007\/s11904-019-00430-z. PMID: 30701404.","DOI":"10.1007\/s11904-019-00430-z"},{"issue":"12","key":"721_CR85","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/OLQ.0000000000001872","volume":"50","author":"DM Higgins","year":"2023","unstructured":"Higgins DM, Riba A, Alderton L, Wendel KA, Scanlon J, Weise J, Gibson N, Obafemi O. Evaluation of the impact and outcomes of a rapid transition to telehealth PrEP delivery at a sexual health clinic during the COVID-19 pandemic. Sex Transm Dis. 2023;50(12):816\u201320. Epub 2023 Oct 9. PMID: 37820240; PMCID: PMC10668045. https:\/\/doi.org\/10.1097\/OLQ.0000000000001872.","journal-title":"Sex Transm Dis"},{"key":"721_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04366-3","author":"S Bonett","year":"2024","unstructured":"Bonett S, Li Q, Sweeney A, Gaither-Hardy D, Huseein S. Telehealth models for PrEP delivery: a systematic review of acceptability, implementation, and impact on the PrEP care continuum in the United States. AIDS Behav. 2024. https:\/\/doi.org\/10.1007\/s10461-024-04366-3. https:\/\/doi-org.offcampus.lib.washington.edu\/.","journal-title":"AIDS Behav"},{"key":"721_CR87","unstructured":"Q Care Plus. PrEP made easy. 2024. Available: https:\/\/qcareplus.com\/. Accessed 13 Sep 2024."},{"key":"721_CR88","unstructured":"Mistr PEP. 2024. Available: https:\/\/heymistr.com\/. Accessed 13 Sep 2024."},{"key":"721_CR89","unstructured":"Mistr Sistr PEP. 2024. Available: https:\/\/heymistr.com\/sistr\/. Accessed 13 Sep 2024."},{"key":"721_CR90","unstructured":"Louisiana Health Hub. TelePrEP Program [Internet]. Available https:\/\/www.louisianahealthhub.org\/teleprep\/ Accessed 27 Jul 2024."},{"key":"721_CR91","doi-asserted-by":"publisher","unstructured":"McKellar MS, Des Marais AC, Chen H, Choi Y, Lilly R, Ayers D, et al. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study. Harm Reduct J. 2024;21(1). https:\/\/doi.org\/10.1186\/s12954-024-00983-2.","DOI":"10.1186\/s12954-024-00983-2"},{"key":"721_CR92","doi-asserted-by":"publisher","unstructured":"Corneli A, Perry B, Des Marais A, Choi Y, Chen H, Lilly R, et al. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV prep and Buprenorphine\/NALOXONE program embedded within syringe services programs: a qualitative descriptive evaluation. Harm Reduct J. 2022;19(1). https:\/\/doi.org\/10.1186\/s12954-022-00718-1.","DOI":"10.1186\/s12954-022-00718-1"},{"issue":"1","key":"721_CR93","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12889-023-15429-w","volume":"23","author":"AR Bazzi","year":"2023","unstructured":"Bazzi AR, Bordeu M, Baumgartner K, Sproesser DM, Bositis CM, Krakower DS, et al. Study protocol for an efficacy trial of the PrEP for Health intervention to increase HIV PrEP use among people who inject drugs. BMC Public Health. 2023;23(1):513. https:\/\/doi.org\/10.1186\/s12889-023-15429-w.","journal-title":"BMC Public Health"},{"issue":"1","key":"721_CR94","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13722-024-00447-9","volume":"19","author":"TS Bartholomew","year":"2024","unstructured":"Bartholomew TS, Plesons M, Serota DP, Alonso E, Metsch LR, Feaster DJ, et al. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services. Addict Sci Clin Pract. 2024;19(1):21. https:\/\/doi.org\/10.1186\/s13722-024-00447-9.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"721_CR95","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13063-023-07899-5","volume":"25","author":"D Goodman-Meza","year":"2024","unstructured":"Goodman-Meza D, Shoptaw S, Hanscom B, Smith LR, Andrew P, Kuo I, Lake JE, Metzger D, Morrison EAB, Cummings M, Fogel JM, Richardson P, Harris J, Heitner J, Stansfield S, El-Bassel N, HPTN 094 Study Team. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study). Trials. 2024;25(1):124. https:\/\/doi.org\/10.1186\/s13063-023-07899-5. PMID: 38360750; PMCID: PMC10870682.","journal-title":"Trials"},{"key":"721_CR96","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1016\/j.dadr.2023.100163","volume":"7","author":"MC Reid","year":"2023","unstructured":"Reid MC, Oliphant-Wells T, Moreno C, Ketchum J, Fitzpatrick T, McMahan VM, Glick SN. High levels of interest in access to free safer smoking equipment to reduce injection frequency among people who inject drugs in Seattle, Washington. Drug Alcohol Depend Rep. 2023;7:100163. https:\/\/doi.org\/10.1016\/j.dadr.2023.100163. PMID: 37214756; PMCID: PMC10193167.","journal-title":"Drug Alcohol Depend Rep"},{"key":"721_CR97","doi-asserted-by":"publisher","unstructured":"Chung EO, Patel SV, Wenger LD, Humphrey JL, Bluthenthal RN, Tookes HE et al. Distributing safer smoking pipes increases engagement with harm reduction services in the United states: Findings from the National Survey of Syringe Services Programs. MedRxiv 2024.06.28.24309683 [Preprint]. July 01, 2024 [cited 2024 Sep 15]. Available from: https:\/\/doi.org\/10.1101\/2024.06.28.24309683","DOI":"10.1101\/2024.06.28.24309683"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-024-00721-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-024-00721-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-024-00721-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:06:36Z","timestamp":1769605596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-024-00721-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s11904-024-00721-0","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"19 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a narrative review of the literature and thus not considered human subjects research. Thus, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors have contributed to this work and agree to submit it for publication in its current form. No data or images are reproduced in this submission without proper permissions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13"}}